Literature DB >> 25139969

Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012.

Terho Heikkinen1, Niina Ikonen2, Thedi Ziegler2.   

Abstract

BACKGROUND: Influenza B virus strains in trivalent influenza vaccines are frequently mismatched to the circulating B strains, but the population-level impact of such mismatches is unknown. We assessed the impact of vaccine mismatch on the epidemiology of influenza B during 12 recent seasonal outbreaks of influenza in Finland.
METHODS: We analyzed all available nationwide data on virologically confirmed influenza infections in all age groups in Finland between 1 July 1999 and 30 June 2012, with the exclusion of the pandemic season of 2009-2010. We derived data on influenza infections and the circulation of different lineages of B viruses during each season from the Infectious Diseases Register and the National Influenza Center, National Institute for Health and Welfare, Finland.
RESULTS: A total of 34 788 cases of influenza were recorded. Influenza A accounted for 74.0% and influenza B for 26.0% of all typed viruses. Throughout the 12 seasons, we estimated that 41.7% (3750 of 8993) of all influenza B infections were caused by viruses representing the other genetic lineage than the one in the vaccine. Altogether, opposite-lineage influenza B viruses accounted for 10.8% of all influenza infections in the population, the proportion being highest (16.8%) in children aged 10-14 years and lowest (2.6%) in persons aged ≥70 years.
CONCLUSIONS: The population-level impact of lineage-level mismatch between the vaccine and circulating strains of influenza B viruses is substantial, especially among children and adolescents. The results provide strong support for the inclusion of both influenza B lineages in seasonal influenza vaccines.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  influenza B virus; quadrivalent influenza vaccines; trivalent influenza vaccines; vaccine mismatch

Mesh:

Substances:

Year:  2014        PMID: 25139969     DOI: 10.1093/cid/ciu664

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  73 in total

1.  Mismatching between circulating strains and vaccine strains of influenza: Effect on Hajj pilgrims from both hemispheres.

Authors:  Mohammad Alfelali; Gulam Khandaker; Robert Booy; Harunor Rashid
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 2.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

3.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

4.  Trends of influenza B during the 2010-2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy.

Authors:  Andrea Orsi; Giuseppina Maria Elena Colomba; Fanny Pojero; Giuseppe Calamusa; Cristiano Alicino; Cecilia Trucchi; Paola Canepa; Filippo Ansaldi; Francesco Vitale; Fabio Tramuto
Journal:  Hum Vaccin Immunother       Date:  2017-08-03       Impact factor: 3.452

5.  Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.

Authors:  Iván Martínez-Baz; Ana Navascués; Francisco Pozo; Judith Chamorro; Esther Albeniz; Itziar Casado; Gabriel Reina; Manuel García Cenoz; Carmen Ezpeleta; Jesús Castilla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

Authors:  Rory D de Vries; Nella J Nieuwkoop; Fiona R M van der Klis; Marion P G Koopmans; Florian Krammer; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

7.  Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.

Authors:  Yuemei Hu; Ming Shao; Yuansheng Hu; Qi Liang; Ningning Jia; Kai Chu; Li Xu; Jing Li; Changgui Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-04-29       Impact factor: 3.452

8.  Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Authors:  Michael J Moser; Yasuko Hatta; Claudia Gabaglia; Adriana Sanchez; Peter Dias; Sally Sarawar; Yoshihiro Kawaoka; Masato Hatta; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2019-07-04       Impact factor: 3.641

9.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

10.  Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages.

Authors:  Karen L Laurie; William Horman; Louise A Carolan; Kok Fei Chan; Daniel Layton; Andrew Bean; Dhanasekaran Vijaykrishna; Patrick C Reading; James M McCaw; Ian G Barr
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.